These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 15629589)

  • 1. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AL; Dong L; Kamat A; Pisters L; Kuban DA
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):14-9. PubMed ID: 15629589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all?
    Kuban D; Thames H; Levy L; Horwitz E; Kupelian P; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):409-14. PubMed ID: 15667960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.
    Horwitz EM; Thames HD; Kuban DA; Levy LB; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Sandler HM; Shipley WU; Zelefsky MJ; Hanks GE; Zietman AL
    J Urol; 2005 Mar; 173(3):797-802. PubMed ID: 15711272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
    Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Demanes DJ; Rodriguez RR; Schour L; Brandt D; Altieri G
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1306-16. PubMed ID: 15817332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.
    Gondi V; Deutsch I; Mansukhani M; O'Toole KM; Shah JN; Schiff PB; Katz AE; Benson MC; Goluboff ET; Ennis RD
    Urology; 2007 Mar; 69(3):541-6. PubMed ID: 17382161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Failure pattern implications following external beam irradiation of prostate cancer: long-term follow-up and indications of cure.
    Hanlon AL; Hanks GE
    Cancer J; 2000 Apr; 6 Suppl 2():S193-7. PubMed ID: 10803836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg DF; Pollack A
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1003-10. PubMed ID: 15752879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
    Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
    Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone.
    Horwitz EM; Uzzo RG; Hanlon AL; Greenberg RE; Hanks GE; Pollack A
    J Urol; 2003 Jun; 169(6):2153-7; discussion 2157-9. PubMed ID: 12771738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
    Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candidates for prostate radioactive seed implantation treated by external beam radiotherapy.
    Seung SK; Kroll S; Wilder RB; Posner MD; Roach M
    Cancer J Sci Am; 1998; 4(3):168-74. PubMed ID: 9612598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer.
    Bellera CA; Hanley JA; Joseph L; Albertsen PC
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1357-63. PubMed ID: 19395198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure.
    Kamat AM; Rosser CJ; Levy LB; Chichakli R; Lee AK; Cheung MR; Pisters LL
    Urology; 2004 Jun; 63(6):1132-7. PubMed ID: 15183966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.